Lin ZH, He Y, Xu HX, Xiao L. Cost-effectiveness analysis of seven treatments vs sorafenib as first-line therapy for advanced hepatocellular carcinoma in China. World J Gastrointest Oncol 2026; 18(4): 113266 [DOI: 10.4251/wjgo.v18.i4.113266]
Corresponding Author of This Article
Hai-Xia Xu, MD, Department of Medical Oncology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, No. 3002 Sungang West Road, Futian District, Shenzhen 518035, Guangdong Province, China. xhx198345@vip.163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Systematic Reviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Apr 15, 2026 (publication date) through Apr 11, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Lin ZH, He Y, Xu HX, Xiao L. Cost-effectiveness analysis of seven treatments vs sorafenib as first-line therapy for advanced hepatocellular carcinoma in China. World J Gastrointest Oncol 2026; 18(4): 113266 [DOI: 10.4251/wjgo.v18.i4.113266]
World J Gastrointest Oncol. Apr 15, 2026; 18(4): 113266 Published online Apr 15, 2026. doi: 10.4251/wjgo.v18.i4.113266
Cost-effectiveness analysis of seven treatments vs sorafenib as first-line therapy for advanced hepatocellular carcinoma in China
Zhi-Huan Lin, Yan He, Hai-Xia Xu, Liang Xiao
Zhi-Huan Lin, Yan He, Hai-Xia Xu, Liang Xiao, Department of Medical Oncology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen 518035, Guangdong Province, China
Co-first authors: Zhi-Huan Lin and Yan He.
Co-corresponding authors: Hai-Xia Xu and Liang Xiao.
Author contributions: Lin ZH and He Y contributed to data collection and analyzation, wrote the first draft of the manuscript as co-first authors; Lin ZH, He Y, and Xu HX mainly revised the manuscript; Xu HX and Xiao L designed the study and wrote the protocol as co-corresponding authors; all authors approved the final version of the manuscript.
Supported by Natural Science Foundation of Shen Zhen City, No. JCYJ20220530151002004.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Corresponding author: Hai-Xia Xu, MD, Department of Medical Oncology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, No. 3002 Sungang West Road, Futian District, Shenzhen 518035, Guangdong Province, China. xhx198345@vip.163.com
Received: August 20, 2025 Revised: November 23, 2025 Accepted: January 14, 2026 Published online: April 15, 2026 Processing time: 231 Days and 7.4 Hours
Core Tip
Core Tip: The economic evaluation of various first-line treatment regimens for advanced hepatocellular carcinoma is crucial, yet such analyses remain scarce. This study conducted a network meta-analysis of 23 first-line regimens for advanced hepatocellular carcinoma and subsequently performed a cost-effectiveness analysis on seven highly efficacious regimens from the perspective of the Chinese healthcare system. The results indicated that lenvatinib combined with transarterial chemoembolization emerged as the most favorable first-line treatment under current economic conditions in China, achieving a 67.9% probability of being the most cost-effective option. This study contributes a novel perspective to inform clinical decision-making for healthcare professionals.
